BioMimetic Therapeutics, Inc. to Provide Results for GEM OS(R)1 Canadian Foot and Ankle Fusion Study

FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the Company will release, after the close of the NASDAQ market, on Thursday, December 13, 2007, follow-up results for the Canadian clinical trial for the use of GEM OS®1 Bone Graft in foot and ankle fusion indications. The Company will host a conference call and audio webcast at 5:00 p.m. EST the same day. Dr. Samuel E. Lynch, president and CEO, members of the Company’s management team, and Dr. Timothy Daniels, lead clinical investigator for BioMimetic’s Canadian GEM OS1 clinical trial, will be available on the call to discuss the study findings.